1. P708: CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY. (23rd June 2022) Authors: Khadadah, F.; Turkina, A. G.; Lomaia, E.; Morozova, E. V.; Shukhov, O. A.; Petrova, A.; Chitanava, T.; Vlasova, J. J.; Kuzmina, E.; Nemchenko, I.; Chelysheva, E. Y.; Bykova, A.; Gurianova, M.; Xenocostas, A.; Busque, L.; Jamani, K.; Cerquozzi, S.; Kuruvilla, P.; Kaedbey, R.; Leber, B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S158: FINAL RESULT OF TKI DISCONTINUATION TRIAL WITH DASATINIB FOR SECOND ATTEMPT OF TREATMENT FREE REMISSION AFTER FAILING FIRST ATTEMPT WITH IMATINIB: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB. (23rd June 2022) Authors: Kim, D.; Atenafu, E.; Forrest, D.; Bence-Bruckler, I.; Savoie, L.; Keating, M.-M.; Busque, L.; Delage, R.; Xenocostas, A.; Liew, E.; Laneuville, P.; Paulson, K.; Stockley, T.; Lipton, J.; Leber, B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗